Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. - Wikidata - awgldk - TriplyDB

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

http://www.wikidata.org/entity/Q39277209

about

Novel therapeutic strategies for multiple myeloma The novel AKT inhibitor afuresertib shows favorable safety, pharmacokinetics, and clinical activity in multiple myeloma Silence of MCL-1 upstream signaling by shRNA abrogates multiple myeloma growth.Loss of serum and glucocorticoid-regulated kinase 3 (SGK3) does not affect proliferation and survival of multiple myeloma cell lines PI3K regulates MEK/ERK signaling in breast cancer via the Rac-GEF, P-Rex1.AKT as a therapeutic target in multiple myeloma.MicroRNA-21 and multiple myeloma: small molecule and big function.Effects of DTX3L on the cell proliferation, adhesion, and drug resistance of multiple myeloma cells.Integrative analysis of signaling pathways and diseases associated with the miR-106b/25 cluster and their function study in berberine-induced multiple myeloma cells.Relevance of the thyroid hormones-αvβ3 pathway in primary myeloma bone marrow cells and to bortezomib action.Modulation of natural killer cell effector functions through lenalidomide/dasatinib and their combined effects against multiple myeloma cells.Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes.Development of a robust flow cytometry-based pharmacodynamic assay to detect phospho-protein signals for phosphatidylinositol 3-kinase inhibitors in multiple myeloma.Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs.Inhibition of the PI3K/AKT/mTOR pathway activates autophagy and compensatory Ras/Raf/MEK/ERK signalling in prostate cancer Rare SNPs in receptor tyrosine kinases are negative outcome predictors in multiple myeloma.Pan-Raf co-operates with PI3K-dependent signalling and critically contributes to myeloma cell survival independently of mutated RAS.PI3K-dependent multiple myeloma cell survival is mediated by the PIK3CA isoform.Metabolic Features of Multiple Myeloma.Detection and Characterization of Circulating Tumour Cells in Multiple Myeloma.Dendrobium mixture regulates hepatic gluconeogenesis in diabetic rats via the phosphoinositide-3-kinase/protein kinase B signaling pathway.

P2860

Q28081590-ADEF9A0E-26E8-4FAD-B6FC-B6486FF1E14C Q34500544-685C2D83-DC69-451B-889C-5DD50295C979 Q34566043-5C767243-715F-4206-824D-07A128F6D816 Q35594600-A2319B69-0B50-43E3-95FE-0A847518204B Q37421358-0911E278-7D4E-458F-B97C-92A1648DE32A Q38218256-48AA7E71-B8CD-499E-A38B-DBA33D3573EA Q38224963-4C5AFC6D-21AE-402B-9FAF-40D4AC45039F Q38698894-B3D366D9-8D8E-4D1B-BD6F-103F014F3205 Q38744898-0E05F520-918A-42C3-AAA1-665E94F25722 Q38972185-B0A5D98D-B956-409E-9941-CDFB81C82B53 Q39168624-6032EF54-D66A-4E0B-BBAA-5E4968E237EC Q39560208-DB483359-AF9B-42FB-88CB-7CC17B74A5FB Q39780696-6FB9A5D1-4D13-4EF4-97C9-FF04C7F251DA Q41057184-9707BC47-541A-45B6-8C83-EEA06E80FC23 Q41345175-AD43B0B8-FF2B-44F6-B8E5-E951AE6D2EF4 Q41768870-158A7647-C1A5-4029-B7B0-7C6F3DD79BF2 Q49021003-788C75BE-E5D5-4505-AEA2-6AA49055788E Q53055574-0CEC2C21-36C3-4E7B-8D25-CD1B74858F55 Q53694850-EF5E375A-EC77-4185-8B1A-79F0383C2052 Q55208548-581E5A13-766A-4315-8D03-69BB48E359EB Q55340375-0F66F84E-67C8-4AA6-8317-353453FE4B92

P2860

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

http://www.wikidata.org/entity/Q39277209

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

@en

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

@nl

type

label

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

@en

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

@nl

prefLabel

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

@en

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

@nl

P1433

Q39277209-B53FD79D-B629-489B-8D47-DAEFDA336D10

P1476

Q39277209-E9059135-2B08-40EF-A011-CB5F9FF3B0A1

P2093

Q39277209-6660621C-7B8E-4958-B213-86DDCF791C84

Q39277209-AA4FF379-7DAC-45E5-B4A2-B00F90F6FF2B

Q39277209-D9138345-25E7-45F3-85CC-0168A4AACAAB

Q39277209-EB576D00-DFF3-4229-A328-2DD127AE6488

Q39277209-FE721D9C-23C2-4DE2-A495-AF926CEE7EB4

P2860

Q39277209-01B1C50B-1519-4F81-A4F0-D6B9F9F602F8

Q39277209-030ECA40-2983-47F3-9A06-70FD8A89ECEA

Q39277209-188E86D4-4E76-4362-A05B-A3E2DD0148C8

Q39277209-2165377F-3CAE-4262-8118-8692DAA88A54

Q39277209-21FEDEC6-C371-4F75-892D-1177A6528311

Q39277209-2639068E-06FE-4FD1-A3EF-240299B35928

Q39277209-366FFDAB-1D01-40E2-B28B-98CC28E530F6

Q39277209-375CD3DC-966B-452D-8744-16022390B87F

Q39277209-37A191B1-96CA-4850-A0B2-9304E1DA2152

Q39277209-3F2A335D-8858-4096-86E6-896F19FAB4C8

P304

Q39277209-ABE305E9-54C9-482F-AC66-C069BFD689EB

P31

Q39277209-0380034D-DFA7-434F-9BB5-E786B01BB28C

P356

Q39277209-2F8FF2DD-2CE8-4F8F-A864-DD385FE68752

P407

Q39277209-B5C6C1BC-70D0-481D-AE5A-3D95BDDEAF07

P433

Q39277209-BBF2A29E-E794-46FB-B52A-C1C2647FA4CC

P478

Q39277209-9AE49264-C938-4DB7-9238-34DBBD1DD862

P50

Q39277209-F9CA86F3-B814-4BDC-ACF9-2E7DAE588CCA

P577

Q39277209-DC1BBFB8-D755-4C5F-AA5B-97E4801FBC89

P5875

Q39277209-174924D3-893D-4797-A67B-566D060305D2

P698

Q39277209-6019E143-B014-4AE2-B0AA-39D55B333287

P356

P1433

British Journal of Haematology

P1476

Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma.

@en

P2093

Cyrus Sayehli

http://www.w3.org/2001/XMLSchema#string

Manik Chatterjee

http://www.w3.org/2001/XMLSchema#string

Ralf C Bargou

http://www.w3.org/2001/XMLSchema#string

Thorsten Stühmer

http://www.w3.org/2001/XMLSchema#string

Torsten Steinbrunn

http://www.w3.org/2001/XMLSchema#string

P2860

Initial genome sequencing and analysis of multiple myeloma

Multiple myeloma

A transforming mutation in the pleckstrin homology domain of AKT1 in cancer

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Oncogenic mutations of PIK3CA in human cancers

The phosphatidylinositol 3-Kinase AKT pathway in human cancer

A mechanistic rationale for MEK inhibitor therapy in myeloma based on blockade of MAF oncogene expression.

Nongenotoxic activation of the p53 pathway as a therapeutic strategy for multiple myeloma.

Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.

Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis.

P304

430-440

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/BJH.12039

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

159

http://www.w3.org/2001/XMLSchema#string

P50

Hermann Einsele

P577

2012-09-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230869468

http://www.w3.org/2001/XMLSchema#string

P698

22985491

http://www.w3.org/2001/XMLSchema#string